Colleen Kusy
Stock Analyst at Baird
(1.37)
# 3,335
Out of 5,090 analysts
53
Total ratings
32.61%
Success rate
-9.97%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Colleen Kusy
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| NUVL Nuvalent | Maintains: Outperform | $112 → $158 | $109.60 | +44.16% | 3 | Nov 18, 2025 | |
| COGT Cogent Biosciences | Maintains: Neutral | $14 → $34 | $38.77 | -12.30% | 1 | Nov 11, 2025 | |
| APLS Apellis Pharmaceuticals | Maintains: Outperform | $50 → $52 | $23.63 | +120.06% | 13 | Oct 31, 2025 | |
| OCUL Ocular Therapeutix | Maintains: Outperform | $17 → $24 | $12.58 | +90.78% | 5 | Oct 3, 2025 | |
| CLYM Climb Bio | Initiates: Outperform | $9 | $1.72 | +423.26% | 1 | Aug 15, 2025 | |
| ELVN Enliven Therapeutics | Maintains: Outperform | $40 → $52 | $21.81 | +138.42% | 3 | Jun 16, 2025 | |
| AGEN Agenus | Maintains: Neutral | $4 → $6 | $3.93 | +52.67% | 4 | Jun 4, 2025 | |
| OCS Oculis Holding AG | Maintains: Outperform | $37 → $41 | $21.68 | +89.11% | 4 | Mar 13, 2025 | |
| CHRS Coherus Oncology | Maintains: Outperform | $4 → $6 | $1.20 | +400.00% | 5 | Dec 5, 2024 | |
| SYRE Spyre Therapeutics | Maintains: Outperform | $50 → $65 | $33.45 | +94.32% | 2 | Nov 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $100 → $75 | $27.78 | +170.03% | 4 | Aug 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $27 → $25 | $11.00 | +127.27% | 1 | Mar 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $255 → $210 | $5.75 | +3,552.17% | 1 | Aug 5, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $30 → $34 | $2.20 | +1,445.45% | 5 | Apr 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $230 | $3.98 | +5,678.89% | 1 | Nov 2, 2021 |
Nuvalent
Nov 18, 2025
Maintains: Outperform
Price Target: $112 → $158
Current: $109.60
Upside: +44.16%
Cogent Biosciences
Nov 11, 2025
Maintains: Neutral
Price Target: $14 → $34
Current: $38.77
Upside: -12.30%
Apellis Pharmaceuticals
Oct 31, 2025
Maintains: Outperform
Price Target: $50 → $52
Current: $23.63
Upside: +120.06%
Ocular Therapeutix
Oct 3, 2025
Maintains: Outperform
Price Target: $17 → $24
Current: $12.58
Upside: +90.78%
Climb Bio
Aug 15, 2025
Initiates: Outperform
Price Target: $9
Current: $1.72
Upside: +423.26%
Enliven Therapeutics
Jun 16, 2025
Maintains: Outperform
Price Target: $40 → $52
Current: $21.81
Upside: +138.42%
Agenus
Jun 4, 2025
Maintains: Neutral
Price Target: $4 → $6
Current: $3.93
Upside: +52.67%
Oculis Holding AG
Mar 13, 2025
Maintains: Outperform
Price Target: $37 → $41
Current: $21.68
Upside: +89.11%
Coherus Oncology
Dec 5, 2024
Maintains: Outperform
Price Target: $4 → $6
Current: $1.20
Upside: +400.00%
Spyre Therapeutics
Nov 13, 2024
Maintains: Outperform
Price Target: $50 → $65
Current: $33.45
Upside: +94.32%
Aug 14, 2024
Maintains: Neutral
Price Target: $100 → $75
Current: $27.78
Upside: +170.03%
Mar 12, 2024
Reiterates: Outperform
Price Target: $27 → $25
Current: $11.00
Upside: +127.27%
Aug 5, 2022
Maintains: Outperform
Price Target: $255 → $210
Current: $5.75
Upside: +3,552.17%
Apr 7, 2022
Maintains: Outperform
Price Target: $30 → $34
Current: $2.20
Upside: +1,445.45%
Nov 2, 2021
Initiates: Outperform
Price Target: $230
Current: $3.98
Upside: +5,678.89%